Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Multiple Sclerosis and Demyelinating Disorders

Fig. 1

From: Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologists

Fig. 1

Choice of initial treatment in patients with RRMS by case scenarios. Note: Responses of only those who reported that they would initiate DMD for each case were calculated. Case scenarios are shown in Table 5. Group 1: 1–3 MS patients under care, Group 2: 4–9 MS patients under care, Group 3: ≥10 MS patients under care. RRMS: relapsing-remitting multiple sclerosis, MS: multiple sclerosis, DMD: disease-modifying drug, SC IFNβ-1b: subcutaneous interferon beta-1b, IM IFNβ-1a: intramuscular interferon beta-1, JCV: John Cunningham virus

Back to article page